India, Oct. 6 -- Lupin Limited has launched Formoflo-G® MDI, described by the company as the world's first fixed-dose triple combination metered-dose inhaler (MDI) for chronic obstructive pulmonary disease (COPD) in India, following approval from the Drug Controller General of India (DCGI).
Formoflo-G® combines Glycopyrronium Bromide, Formoterol Fumarate and Fluticasone Propionate in a single inhaler for the long-term management of moderate to severe COPD. The product is available in a fixed strength and is administered twice daily, offering patients a simplified treatment option.
Lupin said the launch expands its respiratory care portfolio and aims to address the treatment needs of millions of COPD patients in India. The company ...